Inebilizumab-cdon
Inebilizumab-cdon
Inebilizumab-cdon (pronunciation: in-eh-bil-iz-uh-mab cdon) is a monoclonal antibody medication used for the treatment of neuromyelitis optica spectrum disorder (NMOSD).
Etymology
The name Inebilizumab-cdon is derived from the International Nonproprietary Names (INN), with 'Inebilizumab' indicating the specific drug and 'cdon' referring to the target antigen, CDON.
Usage
Inebilizumab-cdon is used primarily for the treatment of neuromyelitis optica spectrum disorder (NMOSD), a rare neurological condition. It is specifically used in patients who are anti-aquaporin-4 (AQP4) antibody positive.
Mechanism of Action
Inebilizumab-cdon works by binding to the CD19 protein on the surface of B cells, a type of white blood cell. This leads to the depletion of B cells, which play a key role in the inflammation that occurs in NMOSD.
Related Terms
- Monoclonal antibody: A type of protein made in the lab that can bind to substances in the body, including cancer cells.
- Neuromyelitis optica spectrum disorder (NMOSD): A rare neurological condition that affects the optic nerves and spinal cord.
- B cells: A type of white blood cell that makes antibodies.
- CD19: A protein found on the surface of B cells.
- Aquaporin-4 (AQP4): A protein that forms a channel for the transport of water across cell membranes.
External links
- Medical encyclopedia article on Inebilizumab-cdon
- Wikipedia's article - Inebilizumab-cdon
This WikiMD dictionary article is a stub. You can help make it a full article.
Languages: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
Urdu,
বাংলা,
తెలుగు,
தமிழ்,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
European
español,
Deutsch,
français,
русский,
português do Brasil,
Italian,
polski